At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- 68Ga-PSMA (drug)
- How long the study runs
- Study runs about 9 months (dates as stated)
- About the drug or intervention
- 68Ga-PSMA — drug: This is an imaging radionuclide tracer and is in chemical form.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- Male
- Number of participants
- 16
- Started
- 2025-03-11
- Last checked
- 2025-06
Plain English Summary
What is this study?
- • Testing a new treatment for malignant melanoma
- • Phase2 - 16 participants
- • This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with malignant melanoma
- • Male only
Where?
- • London - The Royal Marsden NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
More detail
The proposed 'Preoperative Planning PSMA-PET in Melanoma Surgery (PPPIMS)' trial is a Phase 2 study, investigating the ability of PSMA as a biomarker to accurately detect melanoma metastases in patients with palpable lymphadenopathy and oligometastatic melanoma. If proven to have diagnostic utility, it may allow more precise 3D lymphatic mapping and identification of tumour in intricate anatomical areas, resulting in more accurate surgical planning. A more precise delineation of nodal disease and metastasis will result in a more accurate and lesser surgical dissection, and consequent reduction in morbidity. The PSMA-PET-CT will be compared with the standard-of-care imaging, FDG-PET-CT to evaluate utility of this approach. It is of note that FDG-PET CT has a high background FDG uptake normally seen in the brain and liver, and PSMA could potentially be a more favourable tracer if there is less background uptake.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: Male only
What the study is looking for
- ✓Males ≥18 years of age
Who cannot take part
- ✗Patients unable to give voluntary written agreement to take part to participate in this study
- ✗Patients not willing to complete all the study assessments
- ✗Patients who are females
- ✗Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such...
- ✗Patients who have or have previously been diagnosed with prostate cancer
See the full criteria
Where Is This Study? (1 UK site)
The Royal Marsden NHS Foundation Trust
London SW3 6JJ, United Kingdom
How to Get in Touch
Reyhaneh Sadegh Zadeh
Sponsor contactCONTACT